Atrial Fibrillation Global Market Report 2024

The global atrial fibrillation market has grown rapidly in recent years. It will grow from $12.02 billion in 2023 to $13.47 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The observed growth in the historic period can be attributed to factors such as increasing awareness and screening programs for atrial fibrillation, technological innovations in treatment approaches, a rise in healthcare expenditure, ongoing clinical research, drug development initiatives, and considerations of genetic predisposition.

The global atrial fibrillation market is expected to see rapid growth in the next few years. It will grow to $21.66 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The anticipated growth in the forecast period can be attributed to a heightened focus on stroke prevention, the implementation of patient and physician education programs, global initiatives for cardiovascular health, an increase in electrophysiology procedures, customization of treatment plans, and government initiatives aimed at cardiovascular disease prevention. Major trends expected in the forecast period include advancements in diagnostic technologies, a rise in the incidence of atrial fibrillation, improvements in catheter ablation techniques, the emergence of novel oral anticoagulants (NOACs), integration of wearable technologies for monitoring, and an expanding role of telemedicine in atrial fibrillation management. Additionally, advancements in implantable devices are anticipated to contribute to the evolving landscape of atrial fibrillation treatment and care.

The expansion of the atrial fibrillation market is poised to be driven by the escalating elderly population, particularly individuals aged 65 and above who face higher risks of falls due to factors like postural hypotension and mobility issues. The prevalence of conduction disturbances and age-related indicators on electrocardiograms before atrial fibrillation onset in this demographic further underscores this market growth. According to the World Health Organization's October 2022 report, the global population aged 60 and above is projected to reach 1.4 billion by 2030, marking a significant increase from 1 billion in 2020. By 2050, this age group is expected to double to 2.1 billion, with a substantial rise in the population aged 80 and older by 426 million compared to present numbers. Consequently, the burgeoning geriatric populace serves as a primary driver for the growth trajectory of the atrial fibrillation market.

The upward trend in cardiovascular ailments is anticipated to propel the atrial fibrillation market. Cardiovascular diseases encompass a spectrum of conditions impacting the heart and blood vessels, including coronary artery disease, heart failure, and arrhythmias, posing significant risks to overall heart health. The surge in these conditions underscores the pressing need for advanced diagnostic and therapeutic solutions, fueling the growth of the atrial fibrillation market. As reported by the American Heart Association in January 2022, approximately 19.1 million deaths globally were attributed to cardiovascular diseases in that year. Furthermore, the Centers for Disease Control and Prevention highlighted a rise in heart disease-related deaths in the US from 659,041 in 2019 to 695,000 in 2021. Hence, the substantial burden of cardiovascular diseases worldwide is expected to be a pivotal driver for the atrial fibrillation market.

Key players within the atrial fibrillation market are actively introducing innovative products and solutions, such as patient-centric clinical decision support tools, to fortify their market position. Clinical decision support tools (CDST) are software or electronic systems designed to aid healthcare professionals in making informed and timely decisions regarding patient care. These tools are developed to assimilate pertinent clinical information from diverse sources. For instance, in August 2023, GE HealthCare launched CardioVisio, a patient-centered clinical decision support tool designed to assist physicians in evidence-based decision-making aligned with current atrial fibrillation guidelines. CardioVisio offers a comprehensive view of a patient's cardiac history, including past diagnoses, prescribed medications, interventions, and comorbidities. It enables cardiologists to streamline image interpretation and visualize longitudinal patient data critical for understanding disease progression and the patient's healthcare journey.

Leading enterprises within the atrial fibrillation market are leveraging cutting-edge advancements by introducing innovative products and solutions, such as a mapping catheter integrated with distinctive technology, aimed at consolidating their market standing. The mapping catheter constitutes a medical apparatus utilized in electrophysiology procedures, particularly within cardiac electrophysiology, to study the heart's electrical activity for diagnosing and managing various cardiac arrhythmias or irregular heart rhythms. In a notable development in July 2023, Biosense Webster Inc., a US-based company specializing in heart rhythm and heart disorder medical technology and diagnostics, unveiled the OPTRELL Mapping Catheter equipped with TRUEref technology. This tool facilitates high-definition electrophysiological mapping in complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia. Characterized by tiny electrodes arranged in a fixed array formation, the OPTRELL Mapping Catheter employs unique TRUEref technology to provide intelligent insights and high-resolution directional mapping. Clinicians benefit from a clearer comprehension of the arrhythmia's location, aiding in the development of more effective ablation strategies.

In an acquisition move in August 2022, Medtronic PLC, a US-based medical device corporation, acquired Affera, Inc. for an undisclosed sum. This strategic acquisition bolsters Medtronic's cardiac ablation portfolio by integrating Affera's cardiac mapping and navigation platform, a comprehensive amalgamation of diagnostic capabilities, focal pulsed field, and radiofrequency ablation solutions. Affera Inc., a US-based venture-backed medical device company operating within the atrial fibrillation market, contributes to Medtronic's expansion in this domain.

Major companies operating in the atrial fibrillation market report are AtriCure Inc., Johnson & Johnson Private Limited, Abbott Laboratories, C.H. Boehringer Sohn AG & Co. KG, Biotronik Se & Co. Kg, Boston Scientific Corporation, Bristol-Myers Squibb Company, CardioFocus Inc., Sanofi S.A, Medtronic PLC, Biosense Webster Inc., MicroPort Scientific Corporation, Siemens AG, Acutus Medical Inc., AEGEA Medical Inc., Apama Medical Inc., Aria CV Inc., Armetheon Inc., BioSig Technologies Inc., Cardialen Inc., CardioRobotics Inc., CardioInsight Technologies Inc., Circa Scientific LLC, CorWave SA, EpiEP Inc., Farapulse Inc., Fibralign Corporation, Impulse Dynamics NV, JenaValve Technology Inc., Kardium Inc.

North America was the largest region in the atrial fibrillation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the atrial fibrillation market report forecast period. The regions covered in the atrial fibrillation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atrial fibrillation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of atrial fibrillation treatments can be categorized into surgical and non-surgical approaches. Surgical atrial fibrillation treatment involves administering an electrical shock on the outside of the chest to regulate the heartbeat, using paddles or patches. Various technologies, including radiofrequency, laser, cryotherapy, and others, are utilized for treatments, which encompass pharmacological, non-pharmacological, maze surgery, and electric cardioversion. These treatments are applied by various end-users, including hospitals, electrophysiology labs, and ambulatory surgical centers.

This report provides atrial fibrillation market statistics, including atrial fibrillation industry global market size, regional shares, competitors with an atrial fibrillation market share, detailed atrial fibrillation market segments, market trends and opportunities, and any further data you may need to thrive in the atrial fibrillation industry. This atrial fibrillation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atrial fibrillation market includes revenues earned by entities from treatment for sinus bradycardia, premature atrial contractions (PACS), wandering atrial pacemakers, atrial tachycardia, multifocal atrial tachycardia, atrial flutter, and atrial fibrillation (Afib). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.